Medicines pursues generic Angiomax drugmakers
The Medicines Company has filed lawsuits against Teva Parenteral Medicines, Pliva Hrvatska and related entities in the U.S. District Court for the District of Delaware, alleging patent infringement based on abbreviated new drug applications seeking FDA approval to market generic versions of its bivalirudin (Angiomax) product prior to patent expiration.
According to the Parsippany, N.J.-based company, each lawsuit alleges infringement of its U.S. Patent No. 7,598,343, which was issued on Oct. 6, 2009.
Medicines also has patent infringement lawsuits pending against the same parties in the U.S. District Court for the District of Delaware for infringement of its U.S. Patent No. 7,502,727, also covering bivalirudin. The ‘727 patent was issued to Medicines on Sept. 1, 2009, and is scheduled to expire in March of 2010. The company could have obtained a four-year extension had they not missed the deadline to file for extended patent exclusivity by a day.
According to the Parsippany, N.J.-based company, each lawsuit alleges infringement of its U.S. Patent No. 7,598,343, which was issued on Oct. 6, 2009.
Medicines also has patent infringement lawsuits pending against the same parties in the U.S. District Court for the District of Delaware for infringement of its U.S. Patent No. 7,502,727, also covering bivalirudin. The ‘727 patent was issued to Medicines on Sept. 1, 2009, and is scheduled to expire in March of 2010. The company could have obtained a four-year extension had they not missed the deadline to file for extended patent exclusivity by a day.